Photo taken from youtube.com
Nov 15, 2023, 17:25
We are proud to collaborate with MENARINI Group and Natera Oncology on EORTC 2129-BCG TREAT ctDNA – EORTC
EORTC – European Organization for Research and Treatment of Cancer shared
“We are proud to collaborate with MENARINI Group and Natera Oncology on EORTC 2129-BCG TREAT ctDNA, an international, multi-center, randomized, phase III clinical trial on high-risk, ctDNA positive, ER+/HER2- early-stage breast cancer. Read the article here.”
Quoting :
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19
“We are pleased to announce that Signatera will be used in a new international, multi-center breast cancer trial. The randomized, phase III TREAT ctDNA trial will evaluate effectiveness of switching treatment to a new oral endocrine monotherapy called elacestrant in early breast cancer based on the detection of molecular relapse with Signatera.
The trial is being conducted by the EORTC – European Organisation for Research and Treatment of Cancer Breast Cancer Group in collaboration with Natera and MENARINI Group, a leading international pharmaceutical and diagnostics company.
‘Collaborations with leading clinical trial organizations like EORTC are needed as we seek to demonstrate the power of treatment on molecular recurrence across cancer indications,’ said Minetta Liu, M.D., chief medical officer of oncology at Natera. ‘We believe this represents a paradigm shift in a patient’s cancer journey, wherein ctDNA testing may serve as a critical tool to catch relapse earlier, enable treatment while disease burden is still low, and ultimately improve patient outcomes.’
Read more in our press release here.”